| Citation: |
FAN Qianyu, HUANG Qiuyi, CHEN Jian. Advances and Reflections on Neoadjuvant Therapy for Locally Advanced Thyroid Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 290-295. DOI: 10.3971/j.issn.1000-8578.2024.23.1164
|
The vast majority of thyroid cancers show a good prognosis. However, the treatment of locally advanced thyroid cancer presents a huge problem. The wide application of targeted and immunotherapy in neoadjuvant therapy for locally advanced thyroid cancer has become a new therapeutic direction. This article summarizes the research on neoadjuvant chemotherapy, radiotherapy, and targeted therapy and immunotherapy related to various pathological types of thyroid cancer, with a focus on the recent advancements and thoughts on the application of targeted and immunotherapeutic drugs in neoadjuvant therapy. The results provide additional options for the clinical treatment of locally advanced thyroid cancer.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
|
| [2] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [3] |
Megwalu UC, Moon PK. Thyroid Cancer Incidence and Mortality Trends in the United States: 2000-2018[J]. Thyroid, 2022, 32(5): 560-570. doi: 10.1089/thy.2021.0662
|
| [4] |
中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医疗保健国际交流促进会普通外科学分会等. 局部进展期甲状腺癌新辅助治疗中国专家共识(2023版)[J]. 中国实用外科杂志, 2023, 43(8): 841-848. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202308001.htm
Thyroid Surgeon Committee of the Surgical Branch of the Chinese Medical Association, Thyroid Disease Professional Committee of the Chinese Research Hospital Association, and General Surgery Branch of the Chinese Healthcare International Exchange Promotion Association, et al. Chinese expert consensus on neoadjuvant treatment of locally advanced thyroid cancer (2023 edition)[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2023, 43(8): 841-848. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202308001.htm
|
| [5] |
Park H, Park J, Park SY, et al. Clinical Course from Diagnosis to Death in Patients with Well-Differentiated Thyroid Cancer[J]. Cancers (Basel), 2020, 12(8): 2323. doi: 10.3390/cancers12082323
|
| [6] |
Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer[J]. Surgery, 2016, 160(3): 738-746. doi: 10.1016/j.surg.2016.04.027
|
| [7] |
Haddad RI, Bischoff L, Ball D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(8): 925-951. doi: 10.6004/jnccn.2022.0040
|
| [8] |
Onoda N, Sugino K, Higashiyama T, et al. The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study[J]. Thyroid, 2016, 26(9): 1293-1299. doi: 10.1089/thy.2016.0072
|
| [9] |
Besic N, Auersperg M, Dremelj M, et al. Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma[J]. Thyroid, 2013, 23(2): 178-184. doi: 10.1089/thy.2012.0194
|
| [10] |
Besic N, Auersperg M, Gazic B, et al. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study[J]. Thyroid, 2012, 22(2): 131-137. doi: 10.1089/thy.2011.0243
|
| [11] |
Besic N, Dremelj M, Schwartzbartl-Pevec A, et al. Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience[J]. Radiol Oncol, 2015, 49(3): 271-278. doi: 10.1515/raon-2015-0001
|
| [12] |
Besic N, Auersperg M, Us-Krasovec M, et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma[J]. Eur J Surg Oncol, 2001, 27(3): 260-264. doi: 10.1053/ejso.2000.1098
|
| [13] |
Segerhammar I, Larsson C, Nilsson IL, et al. Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution[J]. J Surg Oncol, 2012, 106(8): 981-986. doi: 10.1002/jso.23177
|
| [14] |
Fagin JA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia[J]. J Clin Endocrinol Metab, 1992, 75(6): 1398-1400.
|
| [15] |
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319-328. doi: 10.1016/S0140-6736(14)60421-9
|
| [16] |
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7): 621-630. doi: 10.1056/NEJMoa1406470
|
| [17] |
Zheng X, Xu Z, Ji Q, et al. A Randomized, Phase Ⅲ Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer[J]. Clin Cancer Res, 2021, 27(20): 5502-5509. doi: 10.1158/1078-0432.CCR-21-0761
|
| [18] |
Tsuboi M, Takizawa H, Aoyama M, et al. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report[J]. Int J Surg Case Rep, 2017, 41: 89-92. doi: 10.1016/j.ijscr.2017.10.010
|
| [19] |
Stewart KE, Strachan MWJ, Srinivasan D, et al. Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report[J]. Eur Thyroid J, 2019, 8(2): 102-107. doi: 10.1159/000494880
|
| [20] |
Gay S, Monti E, Trambaiolo Antonelli C, et al. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma[J]. Future Oncol, 2019, 15(24s): 13-19. doi: 10.2217/fon-2019-0099
|
| [21] |
Alshehri K, Alqurashi Y, Merdad M, et al. Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review[J]. Cancer Rep (Hoboken), 2022, 5(2): e1466. doi: 10.1002/cnr2.1466
|
| [22] |
Huang NS, Wei WJ, Xiang J, et al. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm PhaseⅡ Clinical Trial[J]. Thyroid, 2021, 31(12): 1808-1813. doi: 10.1089/thy.2021.0307
|
| [23] |
Zhang Y, Deng X, Ding Z, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report[J]. Medicine (Baltimore), 2021, 100(12): e25191. doi: 10.1097/MD.0000000000025191
|
| [24] |
Grasic Kuhar C, Lozar T, Besic N, et al. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia[J]. Adv Ther, 2021, 38(12): 5684-5699. doi: 10.1007/s12325-021-01940-2
|
| [25] |
Golingan H, Hunis B, Golding AC, et al. Neoadjuvant Lenvatinib In Advanced Unresectable Medullary Thyroid Carcinoma: A Case Report[J]. AACE Clin Case Rep, 2020, 6(2): e73-e78. doi: 10.4158/ACCR-2019-0365
|
| [26] |
Cleary JM, Sadow PM, Randolph GW, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib[J]. J Clin Oncol, 2010, 28(23): e390-e392. doi: 10.1200/JCO.2009.27.4225
|
| [27] |
Jozaghi Y, Zafereo M, Williams MD, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer[J]. Head Neck, 2021, 43(1): E7-E12. doi: 10.1002/hed.26440
|
| [28] |
Zhao X, Wang JR, Dadu R, et al. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study[J]. Thyroid, 2023, 33(4): 484-491. doi: 10.1089/thy.2022.0504
|
| [29] |
Maurer E, Eilsberger F, Wächter S, et al. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage ⅣB and C anaplastic thyroid cancer[J]. Eur Arch Otorhinolaryngol, 2023, 280(3): 1509-1518. doi: 10.1007/s00405-023-07827-y
|
| [30] |
Yang S, Ji D, Xue F, et al. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma[J]. Cancer Rep (Hoboken), 2023, 6(1): e1770. doi: 10.1002/cnr2.1770
|
| [31] |
Damásio I, Simões-Pereira J, Donato S, et al. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report[J]. Eur Thyroid J, 2023, 12(1): e220179.
|
| [32] |
Cabanillas ME, Drilon A, Farago AF, et al. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer[J]. Ann Oncol, 2020, 31: S1086.
|
| [33] |
张文欣, 郭弘洁, 潘孝汇, 等. 免疫检查点抑制剂的研究进展[J]. 药学进展, 2022, 46(12): 910-921. https://www.cnki.com.cn/Article/CJFDTOTAL-YXJZ202212004.htm
Zhang WX, Guo HJ, Pan XH, et al. Research Progress of Immune Checkpoint Inhibitors[J]. Yao Xue Jin Zhan, 2022, 46(12): 910-921. https://www.cnki.com.cn/Article/CJFDTOTAL-YXJZ202212004.htm
|
| [34] |
Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer[J]. BMC Cancer, 2019, 19(1): 196. doi: 10.1186/s12885-019-5380-3
|
| [35] |
Min IM, Shevlin E, Vedvyas Y, et al. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors[J]. Clin Cancer Res, 2017, 23(24): 7569-7583. doi: 10.1158/1078-0432.CCR-17-2008
|
| [36] |
Li H, Zhou X, Wang G, et al. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer[J]. J Clin Endocrinol Metab, 2022, 107(4): 1110-1126. doi: 10.1210/clinem/dgab819
|
| [37] |
Ding J, Li D, Liu X, et al. Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer[J]. Exp Hematol Oncol, 2022, 11(1): 59. doi: 10.1186/s40164-022-00311-z
|
| [38] |
Obata K, Sugitani I, Ebina A, et al. Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer[J]. Int Cancer Conf J, 2016, 5(4): 197-201. doi: 10.1007/s13691-016-0257-7
|
| [39] |
Kitamura M, Hayashi T, Suzuki C, et al. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report[J]. World J Surg Oncol, 2017, 15(1): 24. doi: 10.1186/s12957-017-1096-5
|
| [40] |
Kim M, Ahn J, Song DE, et al. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer[J]. Endocrine, 2021, 71(2): 427-433. doi: 10.1007/s12020-020-02425-y
|
| [41] |
Bertol BC, Bales ES, Calhoun JD, et al. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer[J]. Thyroid, 2022, 32(2): 153-163. doi: 10.1089/thy.2021.0371
|
| [42] |
Shonka DC, Ho A, Chintakuntlawar AV, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment[J]. Head Neck, 2022, 44(6): 1277-1300. doi: 10.1002/hed.27025
|
| 1. |
孔桂香，武玉娟，马崇智，田军，刘娜，徐茜. 甲下恶性黑色素瘤的研究进展. 西北国防医学杂志. 2021(07): 730-735 .
|
Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: